Published in Neurology on February 22, 2012
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol (2015) 1.70
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol (2016) 1.03
Psychosis in Alzheimer's disease. Biol Psychiatry (2013) 0.99
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol (2015) 0.94
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener (2014) 0.93
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One (2013) 0.90
Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. Alzheimers Dement (2013) 0.89
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. Mol Neurodegener (2016) 0.87
Genetics of Psychosis in Alzheimer Disease. Curr Genet Med Rep (2014) 0.85
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol (2016) 0.84
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry (2014) 0.84
Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS One (2013) 0.83
Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biol Psychiatry (2013) 0.81
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther (2015) 0.81
Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. Oncotarget (2015) 0.78
Increased plasma IL-17F levels in rheumatoid arthritis patients are responsive to methotrexate, anti-TNF, and T cell costimulatory modulation. Inflammation (2015) 0.78
Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients. PLoS One (2013) 0.78
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways. Front Psychiatry (2015) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways. J Cancer (2015) 0.77
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol (2015) 0.76
Emerging biomarkers in cognition. Clin Geriatr Med (2013) 0.76
Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty. Mol Med Rep (2016) 0.75
Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75
Disease modification and Neuroprotection in neurodegenerative disorders. Transl Neurodegener (2017) 0.75
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci (1999) 5.12
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Screening for dementia by memory testing. Neurology (1988) 3.93
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Semantic memory and the brain: structure and processes. Curr Opin Neurobiol (2001) 3.77
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Protection against Alzheimer's disease with apoE epsilon 2. Lancet (1994) 2.96
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging (2000) 2.80
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med (2003) 2.28
Identification of novel brain biomarkers. Clin Chem (2006) 2.06
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 1.46
Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol (1992) 1.39
Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement (2010) 1.35
CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology (2009) 1.30
Episodic and semantic memory in mild cognitive impairment. Neuropsychologia (2005) 1.03
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets (2009) 0.97
Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord (2001) 0.94
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem (2000) 4.96
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology (2005) 3.55
Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation (1993) 3.44
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
A longitudinal study of drivers with Alzheimer disease. Neurology (2008) 3.17
Functional brain imaging of young, nondemented, and demented older adults. J Cogn Neurosci (2000) 3.12
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry (2001) 3.09
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Protection against Alzheimer's disease with apoE epsilon 2. Lancet (1994) 2.96
American Academy of Neurology position statement on physician reporting of medical conditions that may affect driving competence. Neurology (2007) 2.79
Myocardial injury in critically ill patients. A frequently unrecognized complication. JAMA (1995) 2.76
Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A (1992) 2.64
Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest (1998) 2.64
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 2.38
A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol (1997) 2.32
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
Thyroid function during pregnancy. Clin Chem (1999) 2.30
In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc Natl Acad Sci U S A (1999) 2.24
BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci (2000) 2.22
A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol (1998) 2.22
Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med (1994) 2.21
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med (2001) 2.21
Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology (2004) 2.20
Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol (2007) 2.18
Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology (1997) 2.13
The value of informant versus individual's complaints of memory impairment in early dementia. Neurology (2000) 2.10
Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. Mayo Clin Proc (2001) 2.10
Optimal use of blood tests for assessment of thyroid function. JAMA (1993) 2.00
Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem (2001) 1.98
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Polymerase chain reaction for detection of Toxoplasma gondii. J Med Microbiol (1990) 1.89
Hereditary dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22. Neurology (1998) 1.85
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology (2009) 1.85
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology (2011) 1.84
Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol (1997) 1.84
Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation (1997) 1.84
Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 1.82
Impaired synaptic plasticity and cAMP response element-binding protein activation in Ca2+/calmodulin-dependent protein kinase type IV/Gr-deficient mice. J Neurosci (2000) 1.81
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol (1994) 1.77
Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet (1999) 1.73
Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol (1988) 1.73
Ethanol-induced neuronal apoptosis in vivo requires BAX in the developing mouse brain. Cell Death Differ (2003) 1.72
Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis Assoc Disord (1993) 1.72
Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci (2000) 1.72
Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab (1978) 1.70
Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. J Am Geriatr Soc (1990) 1.69
Troponin I phosphorylation in the normal and failing adult human heart. Circulation (1997) 1.67
Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem (1997) 1.67
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology (2010) 1.66
Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury. J Pediatr (1997) 1.64
Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem (1999) 1.64
A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet (1998) 1.63
Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology (2008) 1.62
Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci (1998) 1.61
Alzheimer disease and cancer. Neurology (2005) 1.60
Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology (1996) 1.59
Current concepts in the pathogenesis of Alzheimer's disease. Am J Med (1997) 1.58
Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience (2003) 1.51
The CERAD experience, Part VIII: Neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer's disease. Neurology (1995) 1.51
Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology (2001) 1.50
Driving performance in persons with mild senile dementia of the Alzheimer type. J Am Geriatr Soc (1993) 1.50
Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res (2000) 1.49
Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol (1988) 1.48
Characterization of murine Flt4 ligand/VEGF-C. Oncogene (1997) 1.46
The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women. BJOG (2009) 1.46
Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem (1998) 1.45
In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther (2001) 1.44
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol (1999) 1.43
Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv (2002) 1.42
Reliability of clinical nurse specialists in the staging of dementia. Arch Neurol (1989) 1.41
Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol (1992) 1.39
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Reperfusion differentially induces caspase-3 activation in ischemic core and penumbra after stroke in immature brain. Stroke (2003) 1.39
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab (2001) 1.38
Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol (1987) 1.38